Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
75.00 USD   -0.70%
11/23Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
BU
11/17Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
BU
11/15Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility

08/10/2022 | 08:11am EST

Sen. Hassan toured the company’s U.S. headquarters in Portsmouth before meeting and speaking with employees

On Tuesday, Aug. 9, U.S. Sen. Maggie Hassan (NH) joined members of Novocure’s leadership team to tour the company’s U.S. headquarters in Portsmouth, New Hampshire, and learn more about Novocure’s groundbreaking work to extend patient survival in some of the most aggressive forms of cancer.

Following the tour, Sen. Hassan met with Novocure employees to answer questions and provide an update on her work in Washington. In her remarks, Sen. Hassan spoke about the importance of expanding patient access to innovative medical technologies as well as Novocure’s impact as an innovative job creator in New Hampshire.

“It was great visiting Novocure to learn more about the innovative work being done here for the health and well-being of Granite Staters and Americans,” said Sen. Hassan. “I am focused on working across the aisle in order to improve our health care services and technology so that companies like Novocure can continue their critical work. I appreciated the opportunity to speak with Novocure and their staff about how we can keep working together to strengthen health care and support innovative technology to improve health care outcomes.”

“We thank Sen. Hassan for her continued leadership and dedication to ensuring that patients are afforded timely access to the most revolutionary cancer-treating therapies on the market,” said Bill Doyle, Novocure’s Executive Chairman. “Novocure is proud to have Sen. Hassan representing New Hampshire on Capitol Hill, where she continues to champion the needs of patients everywhere. We were honored to host Sen. Hassan here to share more about Novocure’s patient-forward culture of growth and our commitment to bringing more high-quality jobs to the Granite State. We look forward to having her back in Portsmouth for another visit soon.”

About Novocure:

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.


ę Business Wire 2022
All news about NOVOCURE LIMITED
11/23Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
BU
11/17Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-O..
BU
11/15Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
BU
11/15Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
CI
11/14Novocure Secures CE Mark for New Array
AQ
11/11NovoCure Says it Will Initiate Limited Market Release of Transducer Array in Europe Aft..
MT
11/11Novocure Secures CE Mark for New Array
BU
11/04Novocure Ltd : Other Events (form 8-K)
AQ
10/28Wells Fargo Adjusts Price Target on NovoCure to $74 From $70, Keeps Equal Weight Rating
MT
10/28Truist Securities Trims NovoCure's Price Target to $102 From $105, Maintains Buy Rating
MT
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 538 M - -
Net income 2022 -83,2 M - -
Net Debt 2022 113 M - -
P/E ratio 2022 -92,6x
Yield 2022 -
Capitalization 7 871 M 7 871 M -
EV / Sales 2022 14,8x
EV / Sales 2023 14,3x
Nbr of Employees 1 167
Free-Float 98,9%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 75,00 $
Average target price 89,38 $
Spread / Average Target 19,2%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED-0.11%7 871
SHOCKWAVE MEDICAL, INC.48.19%9 551
MASIMO CORPORATION-50.53%7 614
PENUMBRA, INC.-31.80%7 442
GETINGE AB-41.53%6 033
ASAHI INTECC CO., LTD.5.14%5 069